Since GRP78 can be measured in the plasma, further evidence on using plasma GRP78 as a prognostic marker for NSCLC progression as well as the predictive response to Bortezomib treatment could potentially be explored. The gene discussed is HSPA5; the disease is non-small cell lung carcinoma.